Evidence map›Paper›PMID 41608776›Full record

Trial reportJournal of viral hepatitis2026

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.

Qiumin Luo, Wenxiong Xu, Yeqiong Zhang, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of viral hepatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qiumin LuoDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Wenxiong XuDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-0671-697X
Yeqiong ZhangDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiangyong LiDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jing LaiDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jianguo LiDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xingrong ZhengDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Hong DengDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Lubiao ChenDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiang ZhuDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Chan XieDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0001-6344-9380
Liang PengDepartment of Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0001-6184-5750

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515220029Five-Year Plan of Third Affiliated Hospital of Sun Yat-sen University 2024W106Guangzhou Municipal Science and Technology Program key projects 2023B01J1007Guangzhou Municipal Science and Technology Program key projects 2023B03J1287Guangzhou Municipal Science and Technology Project 202102010204National Natural Science Foundation of China 82070611Sun Yat-Sen University Clinical Research 5010 Program 2020007
6 · The paper itself

Abstract

The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e-antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population. This prospective, open-label, randomised controlled trial enrolled HBeAg-negative patients with normal ALT and randomised them 1:1 to either the treatment group (TAF) or the control group (no treatment). The primary endpoint was the reduction in hepatitis B surface antigen (HBsAg) levels from baseline to week 48. A total of 62 patients were enrolled and followed up by 48 weeks (n = 31 per group). No serious adverse events were reported. At week 48, there was no significant difference in the change in HBsAg between the treatment and control groups [0.01 (-0.06, 0.05) vs. -0.05 (-0.12, 0.06) log

Indexed as

AdenineAlanine TransaminaseAntiviral AgentsHepatitis B, ChronicHepatitis B virusTenofovirVirus ReplicationAdultAlanineDNA, ViralFemaleHepatitis B e AntigensHepatitis B Surface AntigensHumansMaleMiddle AgedAdenineAlanineAlanine TransaminaseAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensTenofovirtenofovir alafenamideantiviral treatmentchronic HBV infectionefficacyinactivenegative HBeAg

Identifiers

PMID41608776
PMCPMC12853233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.